Genentech Revenue and Competitors
Estimated Revenue & Valuation
- Genentech's estimated annual revenue is currently $3.4B per year.
- Genentech's estimated revenue per employee is $155,000
Employee Data
- Genentech has 21679 Employees.
- Genentech grew their employee count by -13% last year.
Genentech's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Business Solutions Principal, Operational Excellence, Office the CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | CEO | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | Sr. Administrative Business Partner to Chief Staff | Reveal Email/Phone |
7 | Chief Staff - MSAT (Cell and Gene Therapy) | Reveal Email/Phone |
8 | Chief Privacy Officer; Senior Associate General Counsel and Executive Director, Privacy Law | Reveal Email/Phone |
9 | VP | Reveal Email/Phone |
10 | Chief Diversity Office, Strategic Partnerships & Development | Reveal Email/Phone |
Genentech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $25770M | 49142 | 10% | $68M | $132.6B |
#2 | $21390M | 138000 | 2% | N/A | N/A |
What Is Genentech?
Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fifteen of the currently approved products of biotechnology are based on or stem from Genentech science. Genentech markets ten products directly in the United States.
keywords:N/A
N/A
Total Funding
21679
Number of Employees
$3.4B
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Genentech News
Case Name: Genentech, Inc. v. Sandoz, Inc., Civ. No. 19-78-RGA (D. Del. Mar. 22, 2022) (Andrews, J.) Drug Product and Patent(s)-in-Suit:...
Aviv Regev recruits a 'purple unicorn' for the top post in the computational pillar she's building at Genentech. Two years after Aviv Regev...
Genentech makes strides toward 2025 D&I goal that spans research, in-house staffing and suppliers · FDA expands approval of Gilead's Veklury,...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS) benefit offered by Tecentr ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the company has made the decision to voluntarily withdraw the U.S. accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane, albumin-bound paclitaxel; nab-paclitaxel) for the t ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $42370M | 172527 | 3% | N/A |